REG - Shield Therapeutics - Chief Financial Officer Transition

Shield TherapeuticsAnnouncement

12/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231012:nRSL8483Pa&default-theme=true

RNS Number : 8483P  Shield Therapeutics PLC  12 October 2023

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Chief Financial Officer Transition

 

London, UK, 12 October 2023: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing iron
deficiency with its lead product Accrufer®/ Feraccru® (ferric maltol),
announces that Hans-Peter Rudolf is standing down from his role as Chief
Financial Officer ("CFO") of the Group to pursue other opportunities.
Hans-Peter will step down from this role as of 20 October 2023, and is
available for consulting through to the end of the month. His resignation is
not the result of any dispute or disagreement with Shield on any matters
relating to Shield's financial statements, internal controls, operations,
policies or practices.

 

Shield also announces that Paul Spoors, Group Company Controller since 2019,
will assume additional responsibility and report directly to the Shield's
Chief Executive Officer, Greg Madison, on an interim basis. The Company has
hired an executive search firm to identify a new Chief Financial Officer and a
further announcement relating to this appointment will be made in due course.

 

Greg Madison, Chief Executive Officer, said: "On behalf of the Board, I would
like to thank Hans-Peter for his leadership and contributions to the business
and our efforts to transform Shield into a fast growing commercial specialty
pharmaceutical company with a completely-built-out U.S. commercial team. He
has built a strong accounting and finance team that will provide a solid
foundation for growth. We wish him every success in the future."

 

Hans-Peter Rudolf, outgoing Chief Financial Officer, said: "I would like to
thank the Board and the senior management team for their support during my
time as CFO. I have every confidence in the future success of the business
and, as a shareholder, I wish the team the very best of continued success for
the future."

 

For further information please contact:

 

 Shield Therapeutics plc                                                                         www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                               +44 (0) 191 511 8500

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Patrick Birkholm                                                                    +44 (0)20 7418 8900

 Joint Broker

 Cavendish Capital Markets Ltd

 Geoff Nash/ George Dollemore/Nigel                                                              +44 (0)20 7220 0563
 Birks

 Financial PR & IR Advisor
 Walbrook PR
 Lianne Applegarth/Alice Woodings                                                                +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 Investor Contact (US Advisor)

 LifeSci Advisors, LLC

 John Mullaly                                                                                    +1 617 429 3548 or jmullaly@lifesciadvisors.com

 

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral
therapy for adults with iron deficiency, with or without anemia.
Accrufer®/Feraccru® has a novel mechanism of action compared to other oral
iron therapies and has been shown to be an efficacious and well-tolerated
therapy in a range of clinical trials. More information about
Accrufer®/Feraccru®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com)

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on
addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric
maltol). The Group has launched Accrufer® in the US and Feraccru® is
commercialized in the UK and European Union by Norgine B.V., who also have the
marketing rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialization of Accrufer® / Feraccru® in China, Hong
Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea,
and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFAFWFEDSELS